BRMS1
BRMS1 (breast cancer metastasis-suppressor 1, also known as DKFZP564A063) is a nuclear transcriptional repressor that reduces the metastatic potential of cancer cells. It acts through histone deacetylase complexes and the regulation of NF-kappa-B signalling. Browse Assay Genie's current range of BRMS1 research reagents below, or read on for the biology behind the target.
BRMS1 is a transcriptional repressor. It down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at Lys-310, and it promotes HDAC1 binding to promoter regions. Through this mechanism it lowers the expression of anti-apoptotic genes controlled by NF-kappa-B. BRMS1 also promotes apoptosis in cells with inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. It may be a mediator of metastasis suppression in breast carcinoma.
The BRMS1 gene reduces the metastatic potential, but not the tumorigenicity, of human breast cancer and melanoma cell lines. The encoded protein localises primarily to the nucleus and is a component of the mSin3a family of histone deacetylase (HDAC) complexes. It contains two coiled-coil motifs and several imperfect leucine zipper motifs. Alternative splicing of the BRMS1 gene results in two transcript variants that encode different isoforms. The protein belongs to the BRMS1 family, and mouse and rat each have a Brms1 ortholog.
The official HGNC name is BRMS1 transcriptional repressor and anoikis regulator, and the previous name was breast cancer metastasis suppressor 1. The symbol DKFZP564A063 is a previous alias. These names reflect the dual role of BRMS1 in chromatin-based transcriptional control and in the suppression of metastatic spread, which makes it a common subject in cancer biology research.
BRMS1 reduces the metastatic potential of breast cancer and melanoma cell lines without affecting tumorigenicity, making it a model for studying how metastasis is restrained.
BRMS1 promotes deacetylation of RELA at Lys-310 and down-regulates NF-kappa-B-driven transcription, including anti-apoptotic genes.
As a component of mSin3a family HDAC complexes that promotes HDAC1 binding to promoters, BRMS1 is relevant to studies of transcriptional repression.
BRMS1 promotes apoptosis in cells with inadequate substrate adherence, linking it to anoikis and the survival of detached tumour cells.
BRMS1 is a transcriptional repressor. It promotes deacetylation of RELA at Lys-310, which dampens NF-kappa-B-driven transcription, and it promotes HDAC1 binding to promoter regions. It also promotes anoikis and may thereby inhibit metastasis, including in breast carcinoma.
BRMS1 stands for breast cancer metastasis-suppressor 1, and DKFZP564A063 is an alias. The HGNC name is BRMS1 transcriptional repressor and anoikis regulator. Alternative splicing gives two transcript variants that encode different isoforms.
Mouse and rat both have a Brms1 ortholog. BRMS1 reduces the metastatic potential of human breast cancer and melanoma cell lines without changing tumorigenicity, so it is studied in metastasis. Check the datasheet of any product for its validated reactivity.
Histone deacetylase complex components, NF-kappa-B pathway proteins and other metastasis-related targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9HCU9; product specifications from Assay Genie datasheets.